UPDATE: Nabi Biopharmaceuticals Down Nearly 70% on Disappointing Phase 3 Results

by Eddie Staley, Benzinga Editor
July 18, 2011 10:30 AM | 13 seconds read |
Nabi Biopharmaceuticals NABI is down nearly 70% on disappointing phase 3 results this morning. The company's NicVAX phase III clinical trial did not meet its primary endpoint. Nabi Biopharmaceuticals is currently trading at $1.76, a loss of 68.74%.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Intraday UpdateMoversBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!